E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with liver tumours that have liver surgery performed |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with liver tumours that have liver surgery performed |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficiency of intravenously administered Lidocaine in minor hepatectomy patients |
|
E.2.2 | Secondary objectives of the trial |
To evaluate lidocain's safety and effect on postoperative pain control and postoperative recovery in patients who undergo minor liver surgery |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Age ≥ 18 years. -Patients planned for minor hepatectomy in Lund. -Informed consent in writing.
|
|
E.4 | Principal exclusion criteria |
-ASA score >3 -Chirrosis -Preoperative decreased liverfunction, defined as ASAT/ALAT/bilirubin above twice the upper normal limit -Pregnancy -AV- block >1 without pacemaker -WHO class >2. -Allergy to lidocaine or other local anaesthesia -Heart failure -Epilepsy -Class 3 antiarythmis (such as cordarone) -Ongoing treatment with opioids. -Uncapable, unwilling or language difficulties making patient unable to understand scope of study -concomittant drugs: Erythromycin, clarithromycin, Fluvoxamine, Cimetidine, antiviral-HIV-medication and imidazol-drugs. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoints:-Total opioid consumption the first 24 hours. (mg morfin equivalents) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
-Total opioid consumption the first 48 hours. (mg morfin equivalents) -Postoperative intensity of pain, NRS (numerical rating scale) -Complications (Clavien-Dindo) -Total Intravenous Opioid consumption in the first 24 hours, and after the first 48 hours (mg morfin equivalents) -Total opioid consumption by day 3, 4, 5 (mg morfin equivalenter) -Time to flatus -Toe to bowel movement -Nausea -Vomiting -Length of stay in hospital -Mortality -Lidocaine- and MEGX-koncentration in blood immediately after induction of anestesia , 30 minutes after resection and at the end of infusion. -QoR-40 -adverse events
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Five Days postoperatively for endpoints related to surgery. Mortality will be evaluated after 90 Days. Adverse events will be monitored continously during the first 5 Days. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial will be 90 Days after the last operated patient in the trial as specified in the protocol |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |